What: The 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago, will provide a clinically relevant, multidisciplinary update on the scientific progress in treating thoracic malignancies. The symposium brings together physician specialists and practicing clinicians of the multidisciplinary care team to discuss the evolving management of thoracic cancers. The symposium will integrate scientific abstract presentations with accompanying discussions, poster abstract presentations, as well as “challenging case” presentations in interactive tumor board-style forums.
The two keynote speakers for the Symposium are Kenneth Rosenzwieg, MD, FASTRO, of Mount Sinai School of Medicine in New York, and Corey J. Langer, MD, of Abramson Cancer Center in Philadelphia. Dr. Rosenzwieg will discuss the use of mutational analysis to guide systemic therapy; and Dr. Langer will review the cutting edge, lung cancer research presented at recent national meetings–ASCO, ASTRO and STS (Society of Thoracic Surgeons).
When: Thursday, October 30 – Saturday, November 1, 2014
Where: Chicago Marriott Downtown Magnificent Mile, Chicago
Press Registration: Credentialed journalists from accredited news organizations are invited to attend and report on the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. Press Policies and Registration Form
Press Office Hours: Sheffield Room, 4th Floor, Chicago Marriott Downtown Magnificent MileThursday, October 30, 8:00 a.m. – 4:00 p.m. Central timeFriday, October 31, 8:00 a.m. – 4:00 p.m. Central time
News Briefings: Thursday, October 30, 7:00 a.m.—7:45 a.m. Central time“Staging, Screening and Costs for Lung Cancer” News BriefingModerator: Laurie E. Gaspar, MD, MBA, FASTRO, University of Colorado, Denverhttp://astro.adobeconnect.com/thoracic2014brief1/
Abstracts:104 Lung Adenocarcinoma Staging Based on 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In-Situ (AIS) and Minimally Invasive Adenocarcinoma (MIA)Madhusmita Behera, Winship Cancer Institute of Emory University, Atlanta
13 Low-dose CT Lung Cancer Screening Practices and Attitudes Among Primary Care Providers at an Academic Medical CenterJennifer Lewis, Wake Forest School of Medicine, Winston-Salem, North Carolina
103 Costs of the Diagnostic Workup for Lung Cancer – A Medicare Claims AnalysisTasneem Lokhandwala, Xcenda, Palm Harbor, Florida
Friday, October 31, 7:00 a.m. – 7:45 a.m. Central time “Advances in Radiation Therapy and Targeted Therapy” News BriefingModerator: Stephen M. Hahn, MD, FASTRO, University of Pennsylvania, Philadelphiahttp://astro.adobeconnect.com/thoracic2014brief2/
Abstracts:12 Molecular Profiling in Small Cell Lung Cancer and Lung Neuroendocrine TumorsStephen Liu, MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, D.C.
128 Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes John L. Mikell, Winship Cancer Institute of Emory University, Atlanta
116 A Decade of “50 in 5”: Maturing SBRT Outcomes for Medically Inoperable Early Stage Lung Cancer at Cleveland Clinic Over 10 YearsGregory Videtic, Cleveland Clinic, Cleveland ###
RSS